Patient P-01568

Synthetic patientNBL-101 · Day 108 · 25–34 · F · baseline S14Steering view · 3D Open companion preview

Therapy response

Unstable

Tolerance

Improving

GI state

Improving

Inflammatory state

Improving

Nutritional resilience

Improving

Discontinuation risk

51%

Trajectory

Baseline → today → 30-day prediction · hover a day for signals and events

solid = observed · dashed = predicted

Day 0 NBL-101 started — Baseline state S14
Day 31 NP-02 recommended — Dietary Support Protocol NP-02
Day 32 Patient accepted — Started NP-02 in the companion
Day 42 GI symptom burden −23% vs expected — Dietary Support Protocol NP-02
Day 48 Tolerance state changed — Unstable → Improving
Day 51 Trajectory diverged from prediction — Observed response fell below the model's expected path.
Day 59 GI-04 recommended — GI Support Protocol GI-04
Day 60 Patient accepted — Started GI-04 in the companion
Day 68 GI symptom burden −26% vs expected — GI Support Protocol GI-04
Day 70 ME-01 recommended — Monitoring Escalation ME-01
Day 71 Patient accepted — Started ME-01 in the companion
Day 74 Tolerance state changed — Unstable → Improving
Day 74 Deterioration detected before clinical escalation — Monitoring Escalation ME-01

What changed?

Trajectory began diverging from predicted response on Day 51.

Primary contributors, last 14 days

Inflammatory activity-14
Toxicity-11
GI instability-7
Nutritional resilience+5
Treatment adherence-3

What helped?

Dietary Support Protocol NP-02Day 31
Result: symptom burden −23%
GI Support Protocol GI-04Day 59
Result: symptom burden −26%
Monitoring Escalation ME-01Day 70
Result: deterioration detected before clinical escalation

LIFE OS recommendation

Clinician Review CR-01

67%

probability of meaningful tolerance improvement

284 similar trajectories
100% showed improvement
median effect visible after 5 days

Daily trackers

Molecule settings

The trackers this program marks as important, last 14 days vs the 14 before.

GI burden

Companion

31.9/100

improving · -2.4 vs previous 14 d

Toxicity

Blood

34.4/100

stable · -0.7 vs previous 14 d

Sleep quality

Wearable

27.1/100

stable · -1.1 vs previous 14 d

Energy level

Daily log

3.8/10

stable · -0.1 vs previous 14 d

Stress level

Daily log

5.1/10

stable · -0.2 vs previous 14 d

Steps

Wearable

6,026

worsening · -545 vs previous 14 d

Adherence

Companion

49.6 %

stable · -1.3 vs previous 14 d

This trajectory is doing well — what to keep, what to watch

Steering view →

Heading towards restoration · 52 from the failing basin, 42 from restoration.

Good elements to keep

GI Support Protocol GI-04
intervention · steering +39.1
Dietary Support Protocol NP-02
intervention · steering +37.6
Monitoring Escalation ME-01
intervention · steering +4.1

Main detractors to watch

Low butyrate capacity
hidden · steering -17.5
Low microbial diversity
hidden · steering -7.7
Bacteroides fragilis elevated
hidden · steering -7.4
IL6 high-expression variant
hidden · steering -7.3
Dietary fat load
detractor · GI +4 next day
Insoluble fibre
detractor · GI +3.4 next day

State influencers · digestive

Next-day GI change on high-intake vs low-intake days, last 60 days. Attribution from this patient's own log; sensitivity set by their biology.

Dietary fat load
+4detractor · 95%
Insoluble fibre
+3.4detractor · 95%
Alcohol
+3.2detractor · 95%
Simple carbohydrates
+2.3detractor · 69%
Spicy / capsaicin
+1.4no signal · 43%
Histamine load
-0.8no signal · 21%

Biological layers

Which pathways look influenced, and by which layer of this person's biology.

Pathways under pressure

Butyrate / short-chain fatty acid production ↓60
- MicrobiomeButyrate capacity 44/100
- MicrobiomeF. prausnitzii depleted
Inflammatory signalling ↓45
- DNAIL6 -174 variant raises baseline inflammatory tone
- MicrobiomeBacteroides fragilis expansion
Autonomic recovery ↓45
- WearableResting HR 79 bpm
- WearableShort sleep window
Mucosal barrier integrity ↓40
- MicrobiomeAkkermansia low → thinner mucus layer
- WearableSleep 6.1 h, below personal baseline

DNA

Fictional pharmacogenomic panel

IL6 -174 G/C
Higher inflammatory tone
CYP2D6 Normal metabolizer
Expected exposure

Microbiome

Shannon diversity 2.6 · butyrate capacity 44/100

Akkermansia muciniphilaLow
Faecalibacterium prausnitziiLow
Bacteroides fragilisHigh
Bifidobacterium longumLow
EnterobacteriaceaeHigh

Wearable, last 14 days

daily evolution fed into the runtime

HRV: 47 ms
Sleep: 6.9 h
Steps: 6,742
Resting HR: 81 bpm

Daily log: GI score 32, nutritional resilience 56, adherence 50.

What this patient sees in NostraAI

The content that steers the trajectory: what to eat, what to do, what to take.

Open companion preview

What to eat

Keep meals regular; three to four moderate portions spaced through the day
Include a cooked vegetable portion with each main meal
Add one soluble-fibre source (oats, cooked carrots, banana) to breakfast
Avoid known triggers for now: fried or oily food, dairy, alcohol

What to do

Log the daily check-in; one line is enough
Keep the current walking rhythm
Protect a 7.5-hour sleep window; screens off 30 minutes before
Keep hydration steady: small amounts through the day rather than large volumes at once

What to take

Take the scheduled dose as agreed with your care team
No additional supplements this week
Fictional demo item: continue vitamin D as before

284 biologically similar trajectories

Black: this patient. Green: similar patients whose intervention worked. Orange: similar patients where it did not.

Patient	Similarity	Baseline	Intervention	Outcome	Response today
P-01688	46%	S01	GI-04	improved	40
P-01327	35%	S01	GI-04	improved	56
P-01310	28%	S01	—	—	57
P-01846	28%	S01	—	—	37
P-01813	27%	S01	NP-02	no change	40
P-01816	27%	S01	—	—	35
P-01821	27%	S01	—	—	58
P-01823	26%	S01	—	—	57
P-01313	25%	S01	BR-03	improved	32
P-01635	42%	S02	GI-04	improved	49
P-01452	36%	S02	GI-04	improved	46
P-01459	28%	S02	—	—	51